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Abstract: To adapt the use of GH3.TRE-Luc reporter gene cell line for a quantitative high-throughput screening (qHTS) 
platform, we miniaturized the reporter gene assay to a 1536-well plate format. 1280 chemicals from the Library of Phar-
macologically Active Compounds (LOPAC) and the National Toxicology Program (NTP) 1408 compound collection 
were analyzed to identify potential thyroid hormone receptor (TR) agonists and antagonists. Of the 2688 compounds 
tested, eight scored as potential TR agonists when the positive hit cut-off was defined at ?10% efficacy, relative to maxi-
mal triiodothyronine (T3) induction, and with only one of those compounds reaching ?20% efficacy. One common class of 
compounds positive in the agonist assays were retinoids such as all-trans retinoic acid, which are likely acting via the reti-
noid-X receptor, the heterodimer partner with the TR. Five potential TR antagonists were identified, including the anti-
allergy drug tranilast and the anxiolytic drug SB 205384 but also some cytotoxic compounds like 5-fluorouracil. None of 
the inactive compounds were structurally related to T3, nor had been reported elsewhere to be thyroid hormone disruptors, 
so false negatives were not detected. None of the low potency (>100?M) TR agonists resembled T3 or T4, thus these may 
not bind directly in the ligand-binding pocket of the receptor. For TR agonists, in the qHTS, a hit cut-off of ?20% efficacy 
at 100 μM may avoid identification of positives with low or no physiological relevance. The miniaturized GH3.TRE-
Luc assay offers a promising addition to the in vitro test battery for endocrine disruption, and given the low percentage of 
compounds testing positive, its high-throughput nature is an important advantage for future toxicological screening. 
Keywords: Endocrine disruption, pituitary cells, quantitative high-throughput screening, thyroid hormone receptor, reporter 
gene assay, retinoid-X receptor. 
INTRODUCTION 
The vertebrate thyroid hormone (TH) system isan elabo-
rate signaling network that controls critical processes 
through different life-stages,such as regulation of fuel me-
tabolism [1], proliferation versusdifferentiation, development 
and maintenance of brain function [2-4], thermoregulation 
[5], osmoregulation and renal function [6], seasonal repro-
ductive behaviour and fertility [7, 8], cardiovascular function 
[9, 10], and special senses [11]. Potential alterations to the 
TH system by natural or synthetic compounds present in our  
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food or the environment could therefore have substantial 
implications. In this context, the demonstration that certain 
manufactured chemicals exhibit thyroid hormone-like activ-
ity [12, 13] generated an interest in the many potential ad-
verse outcomes of TH system disruption. The TH signaling 
network relies on efficient and accurate interpretation of 
these extracellular chemical signals by the thyroid receptors 
(TRs) [1]. Thyroid active compounds may interact at the 
level of these TRs but may also generate effects at several 
other targets in a normal functioning TH endocrine system. 
These include TH transport by transthyretin (TTR) or thy-
roxine-binding globulin (TBG) [14]; hormone production 
which depends on iodine uptake [15] and the enzyme thyroid 
peroxidase (TPO) to incorporate iodine onto tyrosinesof thy-
roglobulin [16]; hormone activation or deactivation by iodo-
thyronine deiodinases types I, II, and III (D1, D2, and D3, 
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respectively), which regulate the activity of thyroid hor-
mones via removal of specific iodine substituents [17, 18]; 
UDP glucuronosyltransferases (UGTs) or sulfotransferases 
(SULTs) which conjugate the thyroid hormones and facili-
tate their excretion from the body [19]; or transporters of 
thyroid hormones through the target cell membrane [20]. 
Although in vitro assays have already been developed for 
several of these targets [21], current risk assessment strate-
gies still rely heavily on chemical safety data obtained in 
animal models. This low-throughput approach is relatively 
expensive and may provide an unreliable representation of 
human toxicity. Furthermore, the use of large numbers of 
animals for toxicity testing raises legal and ethical considera-
tions. The development of integrated and intelligent testing 
strategies for toxicity evaluation, such as innovative in vitro 
and in silico approaches, has paved the way for the reduction 
of vertebrate studies. The regulatory system for chemicals 
controlled by the European Chemical Agency (ECHA), 
called Registration, Evaluation and Authorization of Chemi-
cals (REACH) has placed a premium on functional, quantita-
tive, high-throughput, in vitro screening assays (qHTS) for 
the toxicological evaluation of the extraordinarily high num-
ber of natural and synthetic chemicals to be assessed within a 
few years (about 30,000 substances are currently marketed at 
volumes greater than 1 ton/year). In addition, a collaboration 
known as Tox21, comprised of the United States Environ-
mental Protection Agency (US EPA), the US National Insti-
tutes of Health (NIH), and the US Food and Drug Regulatory 
Agency (FDA), has initiated a program of screening a large 
chemical library composed of environmental chemicals and 
pharmaceuticals through different qHTS assays developed 
based on specific biological mechanisms relevant to toxicity 
[22-24]. These screening assays directly assess the effects of 
thousands of chemicals on particular cellular systems or mo-
lecular targets. However, for TR-mediated disruption, a 
functional qHTS assay based on endogenous full-length re-
ceptors is still lacking. Recently, we have developed and 
validated a stably-transfected reporter gene cellular model in 
the TH-responsive rat pituitary tumor GH3 cell line that 
endogenously expresses both TR isoforms [25]. Here, we 
present the development and application of the GH3.TRE-
luc cell line using a qHTS system in order to rapidly identify 
chemicals that alter TR activity, and therefore havethe poten-
tial for endocrine disruption. We miniaturized and optimized 
the GH3.TRE-Luc assay into a 1536-wells plate format for 
assaying potential agonistic, antagonistic and cytotoxic ac-
tivities of the compounds tested. We used the optimized 
qHTS system to test the 1280 compounds of the LOPAC 
library (Library of Pharmacologically Active Compounds) 
[26] and the 1408 chemicals from the National Toxicology 
Program collection (NTP) [27]. To insure that observed ef-
fects were not due to cytotoxicity, we measured intracellular 
ATP content as a cell viability readout. These chemical col-
lections were used for validation of the high-throughput 
screen (qHTS) because of the diverse chemical families they 
contain, some of which are proven to be pharmacologically 
active, and with almost all the compounds previously tested 
in one or more standard toxicological assays. The outcomes 
of this preliminary screen were further examined to identify 
potential false positives and false negatives using the publi-
cally available PubChem Bioassay database. 
MATERIALS AND METHODS 
Cell Line and Culture Conditions 
The GH3.TRE-Luc cell line, developed as described 
[25], stably expresses a modified firefly luciferase reporter 
gene under the regulation of a pair of thyroid hormone re-
sponse elements (TREs). Cells were routinely sub-cultured 
once a week in fresh 75-cm
2
 culture flasks (Corning, Acton, 
MA), in a humid atmosphere at 37°C and 95% air/5% CO2 in 
Dulbecco’s Modified Eagle’s medium/Ham’s F12 
(DMEM:F12, Invitrogen, Carlsbad, CA) supplemented with 
10% Fetal Bovine Serum (FBS, Hyclone, Logan, UT). 
qHTS TRE Luciferase Reporter Gene Assay 
For the TRE luciferase reporter gene assay GH3.TRE-
Luc cells were seeded at 80% confluence in 225 cm
2
 culture 
flasks (Corning, Acton, MA) in regular growth medium and 
cultured overnight. Growth medium was then replaced by 
assay medium [28] (DMEM:F12 supplemented with 10 
?g/ml insulin, 10 ?M ethanolamine, 10 ng/ml sodium se-
lenite, 10 ?g/ml human apotransferrin and 500 ?g/ml bovine 
serum albumin) followed by a 20h incubation. Subsequently, 
cells were detached, re-suspended in assay medium. For 
agonist mode screening, cells were dispensed at 1500 cells/ 5 
?l/well in 1536-well white wall/solid bottom plates (Greiner 
Bio-One North America, NC, USA) using a Flying Reagent 
Dispenser (FRD) (Aurora Discovery, CA, USA). After the 
cells were incubated at 37°C for 4-5 h, 23 nl of compounds 
at 7 to 14concentrations or DMSO control were transferred 
using a Pintoolstation (Wako, San Diego, CA) into each well 
resulting in a final DMSO concentration of 0.46 or 0.92%. 
For antagonist mode screening, cells were dispensed at 1500 
cells/ 4 ?l/wellin 1536-well white wall/solid bottom plates 
(Greiner Bio-One North America) using of FRD (Aurora 
Discovery). After test compounds were added as indicated 
above, 1 ?l of 1 nM final concentration T3 or assay media 
control was dispensed to each well. The assay plates were 
incubated with compound treatment for 24h. After this incu-
bation, 5 ?l of One-Glo luciferase reagent (Promega, Madi-
son, WI) was added and plates were incubated at room tem-
perature for 30 min before reading on a Viewlux plate reader 
(PerkinElmer, Waltham, MA). 
For the primary screening, the 1280 compounds from the 
Library of Pharmacologically Active Compounds (LOPAC, 
Sigma, St. Louis, Missouri, USA) and the 1408 chemicals 
from the National Toxicology Program collection (NTP-
1408) [27] were tested in series of 7 to 14 dilutions with final 
concentrations ranging from 0.6 nM to 92 ?M and 3 nM to 
46 ?M for the NTP and LOPAC collections, respectively. 
The highest concentrations tested were judged to be at the 
very upper range of potential environmental exposures. The 
four left columns in each plate were reserved for controls. 
The control format for the agonist mode plate was column-1 
T3 from 0.3 pM to 4.6 ?M, column-2 100 nMT3 and column 
3 to 4 DMSO only. The control format for the antagonist 
mode plate was column-1 to 2 DMSO only, column-3 to 48 
1 nMT3. 
For rescreening and testing nuclear receptor specific 
ligands, GH3.TRE-Luc cells were seeded at 150,000 
cells/well in 24-well tissue culture plates (Greiner Bio One, 
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Monroe, NC) in DMEM:F12 with 15 mM HEPES (Gibco-
Invitrogen, Grand Island, NY) supplemented with 10% fetal 
bovine serum (Gibco-Invitrogen) and Pen/Strep (Gibco-
Invitrogen). Twenty-four hours later, growth medium was 
replaced by PCM medium for an additional 24h. Cells were 
then incubated for 24h in the presence or absence of the indi-
cated ligands in 0.2 % DMSO. Cell numbers were estimated 
using a BCA protein assay (Thermo Scientific, Rockford, IL) 
and luciferase activity was measured from lysed cells in a 
Hidex Chameleon V microplate luminometer using the Lu-
ciferase Assay System (Promega, Madison, WI). Each dose 
within an experiment was treated in duplicate, and each ex-
periment was performed at least three times.  
Cell Viability Assay 
In order to exclude the compounds that inhibit TR-
induced luciferase reporter gene expression due to cytotoxic-
ity, the LOPAC and NTP libraries were also tested for cell 
viability by measuring intracellular ATP content using a lu-
ciferase-coupled ATP quantitation assay (CellTiter-Glo vi-
ability assay, Promega, Madison, WI). The cells were dis-
pensed at 1500 cells/5 ?l/well in 1536-well white/solid bot-
tom assay plates (GreinerBio-One North America) and the 
assay was run identically to the antagonist screen method 
mentioned above, with addition of 5 ?l/well of CellTiter-Glo 
reagent in place of One-Glo. After 30 minutes incubation at 
room temperature, the luminescence intensity was measured 
using a ViewLux plate reader (PerkinElmer). 
Data Analysis 
The primary data analysis was performed as previously 
described. Briefly, raw plate reads for each titration point 
were first normalized relative to the T3 control (100 nM T3, 
set at 100% for agonist mode; 1 nM T3, set at 0% for antago-
nist mode) and DMSO only wells (basal, set at 0% for ago-
nist mode and -100% for antagonist mode), and then cor-
rected by applying a pattern correction algorithm using com-
pound-free control plates (DMSO plates) [29]. 
Concentration-response titration points for each com-
pound were fitted to the Hill equation yielding concentra-
tions for half-maximal activity for agonists (EC50) or half-
maximal inhibition for antagonists (IC50) and maximal re-
sponse (efficacy) values. The concentration response curves 
of the compounds were classified into four major classes  
(1-4) based on the completeness of curve, goodness of fit, 
and efficacy [29]. Antagonists were identified using the se-
lection criterion that their IC50 values should be at least three 
times lower than the IC50 in the viability assay to exclude 
cases of cytotoxicity. 
RESULTS 
Assay Optimization and Miniaturization in the 1536-Well 
Plate Format 
The GH3.TRE-luc assay was initially miniaturized in a 
1536-well plate with a 5 ?l final assay volume. To find the 
optimal cell density for the well, three different cell numbers 
were tested after treatment with various concentrations of the 
known agonist, T3, ranging from 0.3 pM to 4.6 uM for 24 h. 
The EC50 values of T3 obtained were 0.33, 0.55, and 0.39 nM 
at cell densities of 1000, 1500, and 2000 cells/well, respec-
tively (Table 1). The signal-to-background ratio (S/B) for 
these three cell densities was 7 to 9.5 fold. Z’ factor value 
from the density of 1500 cells/well was 0.88, which was the 
highest compared to other cell densities (1000 or 2000 
cells/well). Therefore, we chose 1500 cells/well for use in 
subsequent studies. 
We optimized conditions to screen for thyroid receptor 
antagonist activity. Antagonist action can be identified based 
on the ability of the test compound to block the effect of a 
sub-maximal concentration of the agonist T3. In order to de-
termine the concentration of T3 to be used for qHTS deter-
mination of antagonist activity, two concentrations slightly 
above the EC50 of T3 (Table 2) were tested. At both T3 con-
centrations the assay showed a similar S/B ratio (3.6 and 3.7 
fold) but the 1 nM T3 group gave a minimal CV (coefficient 
of variation, 7%) compared to the 0.5 nM T3 group (CV, 
11%). Z factors [30] were 0.44 and 0.65 for the 0.5 nM and 1 
nM T3 exposure groups, indicating that 1 nM was a better 
concentration for screening for antagonist activity. This con-
centration represents one that optimizes a large screening 
window without significant loss of sensitivity to detecting 
antagonists due to receptor binding competition with the T3. 
All further inhibition (antagonism) assays were run using 1 
nM of T3 as the agonist. 
Identification of Potential TR Agonists by qHTS 
The qHTS GH3.TRE-luc assay was used to screen the 
LOPAC and NTP libraries for TR agonists and antagonists 
to provide a proof of principle for its use as a newly devel-
oped biomolecular screening tool. Structures of representa-
tive compounds that showed positive responses in the qHTS 
assay are shown in Fig. (1). For agonist screening, the  
concentration titration of T3, used as a positive control, was  
Table 1. Assay Optimization in 1536-well Format.  
Cells/well (5?l) S/B EC50 (nM) Z’ factor 
1,000 9.18 0.33 ± 0.032 0.76 
1,500 7.13 0.55 ± 0.036 0.88 
2,000 9.49 0.39 ± 0.038 0.76 
Cells were plated 4 h prior to assay and stimulated with T3. Signal-to-background ratio (S/B) was calculated comparing the response of 4.6 μM T3 to DMSO controls. EC50 values 
were calculated from full dose response curves (n=3). Z’ factor was calculated using T3 EC100 (n=3). 
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Table 2. T3 Concentration Optimization for Antagonist Mode Screening in 1536-well Format.  
T3 (nM) S/B CV (%) Z’ factor 
0.5 3.6 11.1 0.44 
1 3.7 7.0 0.65 
Cells were plated 4 h prior to assay and stimulated with T3. Signal-to-background ratio (S/B) was calculated comparing the response of the respective T3 concentrations to DMSO 
controls. Coefficient of variation (CV) and Z’ factor were calculated using the indicated T3 concentrations (n=2). 
 
Fig. (1). Chemical structures. A) Triiodothyronine (T3), B) Thyroxine (T4), C) Retinoic acid, D) 13-cis-retinoic acid, E) Trans-retinal, F) 13-
cis-retinal, G) CGP-7930, H) CGP-13501, I) SKF-89145 hydrobromide, J) 4-Hydroxybenzhydrazide, K) Tranilast, L) NS-1619, M) SB 
205384, N) 5-Fluorouracil and O) 1-Acetyl-2-phenylhydrazine. 
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Fig. (2). The intra-plate T3 dose-response curves for 27 different plates. In each plate T3 was used as positive control. After plating at 
1500 cells/well in 1536-well plates and incubated for 4 h, cells were stimulated with the indicated concentration of T3 for 24 h. Log M T3 
concentrations are indicated on the x-axis. 
 
Table 3. Screening Statistics for LOPAC and NTP Libraries.  
 Agonist Mode Antagonist Mode 
Library CV (%) S/B Z’ factor CV (%) S/B Z’ factor 
NTP 9.21± 1.81 7.42± 0.51 0.77± 0.05 7.25± 3.77 4.71± 0.29 0.65± 0.08 
LOPAC 11.04± 1.99 6.88± 0.54 0.82± 0.05 7.83± 1.27 3.37± 0.18 0.76± 0.04 
Coefficient of variation (CV) calculated from control and low concentration plates. Signal-to-background ratio (S/B) and Z’ factor for agonist and antagonist mode determined for 
100nM T3 and 1nM T3, respectively. 
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Fig. (3). Contd…. 
 
 
Fig. (3). Examples of agonists identified in the LOPAC and NTP libraries screening. Open circles, cell viability as a percentage (%) of 
vehicle control values; closed circles, luciferase activity as a % of vehicle control values, on the right and left y-axes respectively. Ligand 
concentrations in mM are indicated on the x-axis. 
 
performed in each plate. The control dose-response curves of 
T3 were well reproduced in all 27 plates used for the screen-
ing of the two libraries, including 6 DMSO plates, with an 
EC50 average of 0.66 ± 0.13 nM (Fig. 2). T3 controls aver-
aged a signal-to-background ratio of 6.88 and 7.42 and the 
average Z factor was 0.82 and 0.77 in the LOPAC and NTP 
libraries screen, respectively (Table 3). Of the 1280 com-
pounds from the LOPAC library, 6 (0.5%) were identified as 
potential TR agonists (Fig. 3), with the positive hit cut-off 
being compounds that gave a ?10% efficacy. The potency 
and efficacy of these compounds are listed in Table 4. Of the 
1408 compounds from the NTP library, 2 (0.1%) were iden-
tified as potential TR agonists, with the positive hit cut-off 
being compounds that gave a ?10% efficacy. The potency 
and affinity of these compounds are listed in Table 5. In or-
der to evaluate the reproducibility of the hits in the qHTS 
format, the LOPAC library was re-screened three times. All 
6 compounds identified from the primary screen showed 
similar activity in the re-screen (Table 4). When, for defining 
TR agonist activity, the positive hit cut-off was set at ?20% 
efficacy, only one TR agonist, retinoic acid, was identified in 
the LOPAC library and none in the NTP library. Close 
evaluation of the dose response curves for the compounds 
that did not induce ?20% efficacy, revealed that at the high-
est dose levels tested, 46 or 92 ?M, maximum agonist activ-
ity may not yet have been reached for some of the com-
pounds. However, given that the highest concentrations 
tested were generally considered to be at the upper end of 
possible exposure levels, we conclude that those compounds 
may not represent effective TR agonists. Furthermore, none 
of these compounds has structural characteristics that resem-
ble the thyroid hormones T3 and T4 (Fig. 1), providing addi-
tional support for the conclusion that they may not represent 
effective direct TR agonists. 
Retinoids detected as positives in the qHTS assay are 
likely acting as agonists via RXRs and not RARs, or 
RXRs complexed with permissive liver –X receptors 
(LXRs) 
In both the LOPAC and NTP1408 libraries, Vitamin A 
derivatives (retinoids) scored as positive hits in the agonist 
mode assay. This raised the possibility that in addition to the 
TRs, the system was responsive to retinoic acid receptors 
(RARs) or retinoid X receptors (RXRs), either alone or in 
known permissive heterodimer complexes with other nuclear 
receptors such as the liver X receptors (LXRs) [31]. How-
ever, neither the RAR-specific ligand TTNPB nor the LXR-
specific ligand T0901317 activated the reporter gene, under 
conditions where both T3 and all-trans retinoic acid showed 
the expected induction profiles (Fig. 4). 
Identification of Potential TR Antagonists by qHTS 
To identify potential TR antagonists using this 
GH3.TRE-luc assay, the LOPAC and NTP libraries were 
screened in the antagonist mode, where cells were exposed  
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Table 4. Potency and Efficacy for Compounds Identified in the LOPAC Library Screening.  
Agonists Potency, ?M (Re-Screen) Efficacy, % (Re-Screen) 
retinoic acid 0.8 22.2 
CGP-7930 2.7 (2.6) 18.2 (18.0) 
CGP-13501 2.8 (2.3) 16.8 (15.0) 
13-cis-retinoic acid 6.4 (2.9) 18.8 (15.5) 
SKF-89145 hydrobromide 21.9 (20.6) 10.9 (16.5) 
4-hydroxybenzhydrazide 24.6 (26.0) 11.5 (17.5) 
Antagonists 
Tranilast 0.7 (0.8) -86 (-81.8) 
SB 205384 2.6 (2.5) -75 (-73.0) 
NS-1619 5.2 (13.4) -58 (-75.7) 
5-fluorouracil 5.2 (3.1) -72 (-71.1) 
Potency (EC50 and IC50) values were calculated from full dose response curves in the absence and presence of T3 (1nM), respectively. Efficacy was defined as percentage of maximal 
induction (agonist mode) or inhibition (antagonist mode) relative to T3 set at 100% (100 nM for testing of agonist and 1 nM for antagonist activity). Average of re-screen values listed 
in parentheses. 
Table 5. Potency and Efficacy for Compounds Identified in the NTP Library Screening.  
Agonists Potency, ?M Efficacy, % 
13-cis-retinal 7.1 11.8 
trans-retinal 14.9 11.4 
Antagonists 
5-fluorouracil 6.7 -86.7 
1-acetyl-2-phenylhydrazine 10.6 -87.5 
Potency (EC50 and IC50) values were calculated from full dose response curves in the absence and presence of T3 (1nM), respectively. Efficacy was defined as percentage of maximal 
induction (agonist mode) or inhibition (antagonist mode) relative to T3 set at 100% (100 nM for testing of agonist and 1 nM for antagonist activity). 
 
Fig. (4). GH3.TRE-LUC cells are activated by T3 and all trans retinoic acid but not RAR or LXR specific ligands. A. Dose response 
curve of T3 induced reporter gene luciferase values in a 24 well format, normalized to total protein values. B. Lack of induction of the reporter 
gene luciferase activity by any concentration of an LXR specific ligand (T0901317). C. Low induction of the reporter gene luciferase activity 
by all trans retinoic acid (ATRA; black bars) consistent with the qHTS results, but not by the RAR specific ligand TTNPB (white bars). Con-
centrations of ligands in nM (for T3) and μM (all other compounds) are indicated on the x-axis. 
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to the test compounds in the presence of 1 nM T3, and the 
ability of the compounds to inhibit T3-mediated TR activa-
tion was measured. The average signal-to-background ratio 
was 3.37 and 4.71, and the average Z factor was 0.76 and 
0.65 for the LOPAC and NTP libraries, respectively. To as-
certain that the inhibitory effect of the potential hits was not 
due to cytotoxic effects, a cell viability screening was per-
formed in parallel. Compounds that are known inhibitors of 
luciferase activity or expression, such as cycloheximide that 
is a potent translation inhibitor present in the LOPAC li-
brary, were removed from further consideration as an addi-
tional filter. From the LOPAC screen, 4 compounds (0.3%) 
were identified with an IC50 that was 3-fold lower than their 
viability IC50. The potency and efficacy of these compounds 
are listed in Table 4 and graphs are given in Fig. (5). From 
the NTP library, 2 compounds (0.1%) were identified using 
the same selection criteria. The potency and efficacy of these 
compounds are listed in Table 5 and graphs are given in  
Fig. (5). In order to evaluate the reproducibility of the hits in 
the qHTS format, the LOPAC library was also screened an 
additional three times. All 4 compounds of interest were con-
firmed in the re-screening assays (Table 4).  
Altogether the data presented indicate reproducibility and 
provide a first proof of principle that the GH3.TRE-luc assay 
is robust and can be utilized to screen large compound librar-
ies in the 1536- well plate format for potential TR agonist as 
well as antagonist activity. 
DISCUSSION 
In the present study, we developed a quantitative high-
throughput screen (qHTS) for potential TR agonist and an-
tagonist activity that was based upon the recently developed 
in vitro reporter gene assay using the stably transfected 
GH3.TRE-Luc cell line [25]. The assay was miniaturized 
and validated in a 1536-well plate format. Subsequently the 
1280 compounds of the LOPAC library and the 1408 com-
pounds of the NTP collection were tested for their TR ago-
nist or antagonist activity. Of the 2688 compounds tested in 
the qHTS 8 (0.3%) or 1 (0.04%) were found to be TR ago-
nists depending on whether the positive hit cut off was de-
fined at ?10% or ?20% efficacy. None of the inactive com-
pounds was structurally related to T3, nor had been reported 
elsewhere to be a thyroid hormone disruptor, so false nega-
tives do not appear to be present in the screen. Furthermore, 
none of the low potency TR agonists had structural charac-
teristics that resemble the thyroid hormones (Fig. 1), provid-
ing further support that they may not represent effec-
tive,direct TR agonists, and therefore may not activate the 
luciferase gene through direct binding to the TR ligand-
binding pocket. Defining TR agonists in the qHTS with a hit 
cut off of ?20% efficacy at 100 μM may avoid identification 
of positives that are only very weak agonists and/or not 
likely to be acting through the ligand-binding pocket. Over-
all, the GH3.TRE-Luc cells performed very well in an auto-
mated 1536-well plate format. The CV slightly varied be-
tween 7-11%, but it was well within the performance stan-
dards for comparable assays in 1536-well plate format [27]. 
We used these two chemical collections to validate the 
highthroughput screen (HTS) because of their diverse 
chemical spaces, containing compounds proven to be phar-
macologically active, and with almost all compounds previ-
ously tested in one or more standard toxicological assays. 
They do not, however, specifically contain compounds 
known for their in vivo or in vitro thyroid hormone disrupt-
ing potency. Not included in the assays were the known T3- 
and T4-like compounds, Tetrac (3,5,3’,5’-tetraiodothyr-
oacetic acid) and Triac (3,5,3’-triiodothyroacetic acid),or any 
OH-PCBs (hydroxylated polychlorinated biphenyls), or 
PBDEs (polybrominated diphenylethers), which had been 
shown previously to be active in the GH3.TRE-Luc assay 
[25]. The LOPAC library contains pharmacologically active 
compounds, including many cytostatic compounds that could 
cause growth inhibition thereby reducing luciferase activity. 
For compounds that do not directly antagonize TR activity, 
cell viability and TRE-Luc inhibition IC50’s will be similar. 
Therefore, it is important to quantify cell viability and to 
calculate the ratio between cell viability and the TRE-Luc 
inhibition IC50s. When this ratio is less than 3, we assumed 
the compound to be merely cytotoxic instead of potentially 
antagonistic of TR activity; this approach has been used be-
fore for other reporter gene screens [32]. One of the most 
potent TRE-Luc antagonists identified in the present screen 
was the anti-cancer drug 5’-fluorouracil, inducing a full con-
centration-response curve without apparent cytotoxicity over 
the range of concentrations used within the 24 h treatment 
(Fig. 5). For known cytotoxic compounds like this, it would 
be worthwhile to evaluate cytotoxicity by alternative meth-
ods to provide higher confidence in interpretation of these 
findings. It is of interest to note that one of the side effects of 
5-fluorouracil is cardiotoxicity, the mechanism of which is 
still poorly understood [33] but has not been linked to TR 
action to date. In addition, compounds like 5’-fluorouracil 
induce p53, which in turn is known to interact with and in-
hibit TR function [34, 35]. Other potential modes of action 
of antagonistic compounds are possible that do not require 
direct TR binding, including inhibition of hormone uptake, 
induction of hormone export, induction of Type III deio-
dinase, or inhibition of TR coactivator expression or enzy-
matic activity. As the cells are used in larger chemicals 
screens, antagonism via a spectrum of TH- and TR-
associated activities versus inhibition of luciferase activity or 
cell viability will be important to discern in secondary 
screens. 
The most active agonists with EC50values lower than 10 
μM were retinoids detected in both libraries (retinoic acid, 
trans-retinal, 13-cis-retinoic acid and 13-cis-retinal), and the 
positive allosteric modulators of the GABA receptors GCP-
7930 and GCP-13501 (Fig. 3). GABA itself was present in 
the LOPAC library but did not show any response in this 
assay, meaning that the GCP compounds may not be activat-
ing the reporter gene via the GABA receptor. Retinoic acid is 
a known direct agonist of both the RAR and the TR het-
erodimer partner RXR, and the other retinoids may be con-
verted to RAR and/or RXR agonists by intracellular metabo-
lism and isomerization [36]. However, RXRs are generally 
thought to form “nonpermissive” heterodimers with TRs, 
RARs,and Vitamin D receptors meaning that RXR ligands 
are not thought to be able to bind and activate in those com-
plexes. Other nuclear receptors like peroxisome proliferator 
activated receptors (PPARs) or liver X receptors (LXRs) 
form “permissive” heterodimers with RXRs that can be acti-
44     Current Chemical Genomics and Translational Medicine, 2014, Volume 8 Freitas et al. 
vated by agonists that bind to either partner. In addition, 
RARs can heterodimerize with TRs and activate the DR4 
elements as used in this assay, to some degree in transient 
transfection assays, in addition to their more preferred DR2 
or DR5 arrangements that promote silent, nonpermissive 
complexes with RXRs [37]. Furthermore, RXR/LXR het-
erodimers preferentially transactivate DR4 elements, and 
GH3 cells express functional RXRs [38, 39], RARs [38], and 
LXRs [40]. However, RARs and LXRs do not activate the 
reporter gene in these cells as judged by the lack of activity 
of specific synthetic ligands for these receptors. Thus, it ap-
pears likely that the retinoid activity is mediated by RXRs in 
these cells. Interestingly, the status of RXR as a permissive 
versus non-permissive partner is defined by the specific cell 
system used for evaluation. A series of previous studies 
demonstrated permissive actions of RXRs specifically in 
pituitary derived cells but not the other cell types [41, 42]. In 
these rat pituitary derived GH3 cells, RXR in the RXR:TR 
heterodimer may be permissively modulated by RXR 
ligands, and thus representing an important functional com-
ponent of TR signaling in a cell type dependent manner. This 
would also explain the agonist-like behavior of retinoids in 
the GH3.TRE-Luc assay without any structural resemblance 
to T3 or T4. Comparison between the reporter gene activation 
in the GH3.TRE-Luc versusother cells where RXRs are not 
permissive in TR heterodimers could be used to filter out 
RXR-active compounds. 
The reporter gene induction potency of other compounds 
that do not structurally resemble T3, is less than that of true 
Fig. (5). Examples of antagonists identified in the LOPAC and NTP libraries screening. Open circles, cell viability as a % of 1 nM T3 
alone values; closed circles, luciferase activity as a percentage (%) of 1 nM T3 alone values, on the right and left y-axes respectively. Ligand 
concentrations in μM are indicated on the x-axis. 
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TR-agonists such as the T3-like OH-BDEs [25]. Therefore 
the cut-off of a maximum efficacy of ?20% is also of use to 
filter out these compounds that are less likely to function as 
true TR agonists. These less effective activators could still be 
of interest as they may interact with pathways indirectly 
modulating TR activation, such as interactions with co-
regulators or epigenetic modifications like effects on DNA 
methylation, chromatin structure or miRNA expression pat-
terns, for example.  
Important secondary assays in cell lines and in animals 
should follow to determine whether the GH3.TRE-LUC 
qHTS assay has good predictive power for effects on thyroid 
hormone signaling in vivo. For example, we are currently 
testing agonists and antagonists from this and subsequent 
larger screens against endogenous thyroid hormone respon-
sive genes in the GH3.TRE-LUC cells. A number of TH 
regulated genes are expressed in GH3 cells, including the 
growth hormone gene that contains the first identified TRE 
[43]. Compounds affecting endogenous genes are then pri-
oritized for molecular mode of action studies (ligand bind-
ing, TRE binding, co activator or corepressor recruitment 
and other endpoints). Such prioritized compounds will then 
be tested further in vivo.We plan to first use the induced and 
spontaneous Xenopus laevis metamorphosis assays that we 
have used for a number of years to screen synthetic TR ago-
nists and antagonists [44, 45], given the strong conservation 
of the TRs and other signaling components among verte-
brates [46]. Certainly, studies in euthyroid and hypothyroid 
rodents, during critical windows of development and in the 
adult may follow for those compounds affecting endogenous 
genes in cell lines and tadpole development in vivo.  
CONCLUSION 
Taken together, the results obtained in the present study 
demonstrate the potential of the qHTS assay developed here 
for the identification of novel compounds acting via a TR-
mediated mode of action. The miniaturized GH3.TRE-Luc 
assay offers a promising addition to the in vitro test battery 
for endocrine disruption, and that, given the low percentage 
of compounds testing positive, its high-throughput nature is 
an important advantage for future toxicological screening. 
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